Reviewed by Dr. Golsa Gholampour, MDMedically reviewed by a licensed healthcare professional. Last updated April 2026.
Key Takeaways
- "Microdosing" GLP-1s means staying at a smaller-than-label dose long-term, usually somewhere between 25% and 50% of the standard maintenance dose, by intent rather than as part of a slow titration.
- Patients try microdosing for four main reasons: managing side effects, stretching cost, planning around fertility, and extending the medication's effective lifespan once they hit goal weight.
- The practice is almost entirely anecdotal at trial quality. There is no Phase 3 data on microdosing semaglutide or tirzepatide yet.
- Most clinicians who support microdosing require it be done under their oversight, not with DIY syringe math from a Reddit thread.
- The legal status of compounded tirzepatide changed in February 2026 when it came off the FDA shortage list, restricting where you can legally microdose tirzepatide outside the brand-name pen.
If you have spent any time on the Reddit weight-loss subs lately, you have seen the term. Microdosing. Someone posts about how they are doing 0.25mg of semaglutide instead of the prescribed 1.7mg, sleeping better, eating normally, still down two pounds this week. Or they have hit goal weight and want to know if they can stretch the last vial by cutting their dose in half.
I will be direct: there is not a randomized controlled trial that says "microdose your GLP-1 and you will get X% of the benefit at Y% of the cost." What there is, instead, is a growing collection of clinicians who have started prescribing lower-than-label doses for specific reasons, plus tens of thousands of patients who self-experiment and post about it. This guide explains where the practice came from, who it is actually for, what the limited data suggests, and how to talk to your provider about it without getting waved off.
What "microdosing" actually means in 2026
In the most common usage, microdosing a GLP-1 means taking somewhere between 25% and 50% of the maintenance dose the drug's official label calls for. With Wegovy that means roughly 0.25mg to 1.2mg weekly instead of the 2.4mg target. With Zepbound it means 2.5mg to 7.5mg weekly instead of the 15mg ceiling. The dose ranges differ a bit per practitioner; there is no formal definition.
A few things to flag right away:
- This is not quite the same as the slow-titration starter doses (the 0.25mg and 0.5mg semaglutide steps that come with every new prescription). Microdosing typically means staying at a low dose long-term, by intent, after escalation is no longer being pursued.
- It is not the same as splitting a single weekly dose into multiple smaller injections across the week. Some prescribers do both at once, but they are different concepts. We covered the splitting angle separately in our tirzepatide microdosing post.
- It is not the same as "psychedelic microdosing." Different drug class, different concept, just shared terminology that took off online and got attached to GLP-1s.
Four reasons people microdose GLP-1s
Most patients who try this are motivated by one of these:
1. Managing side effects
This is the biggest one. The full maintenance dose works for weight loss, but if the nausea, vomiting, or sulfur burps are unbearable, some patients negotiate a sustained lower dose with their provider rather than abandon the medication entirely. The trade is real: probably less weight loss, definitely fewer side effects. For some patients, "less weight loss with no side effects" beats "more weight loss with daily nausea."
2. Stretching cost
A 4-pen month of Zepbound at the 12.5mg KwikPen pricing is about $499 through LillyDirect Self Pay. A patient injecting half-doses turns that into roughly two months of medication. For someone paying out of pocket without insurance coverage, the math is hard to argue with, even when the outcomes data is limited. Compounded telehealth programs that price by dose can offer a cleaner version of the same savings without the syringe math.
3. Maintenance after reaching goal weight
This use case has the most momentum among obesity medicine specialists right now. Once a patient hits their weight goal, the question becomes how to sustain the result without staying on a maximum dose forever. Recent surveys of telehealth providers and obesity clinicians show meaningful adoption of "maintenance microdoses," typically 25% to 50% of the dose used during active weight loss. We covered the data on this trend in our stopping GLP-1s and weight regain post.
4. Fertility and pregnancy planning
For couples planning a pregnancy, GLP-1s have to be discontinued. The label calls for a 2-month washout before conception. Some patients work with their providers to step down to microdoses during the months leading up to that washout, both to ease the metabolic transition and to avoid the rebound that can come with sudden discontinuation. Our GLP-1 male fertility coverage covers the broader metabolic-hypogonadism angle for men.
What the data actually shows
Honest answer: not much, at least not at trial quality. Here is what we have:
- STEP and SURMOUNT trial subgroup data. The pivotal trials for Wegovy (STEP 1-4) and Zepbound (SURMOUNT-1) included starter and intermediate doses on the way to maintenance. Patients on lower doses lost less weight on average, but the relationship was not strictly linear. The 1.0mg semaglutide arm in some studies pulled close to the 2.4mg arm at 68 weeks, just with a longer ramp.
- Real-world telehealth aggregates. Several large compounded-semaglutide telehealth providers have published patient outcome aggregates showing meaningful weight loss at sub-maintenance doses, but the data is self-reported, not adjudicated, and selection-biased toward people who stayed in the program.
- The maintenance question. The closest thing to a real trial is the Phase 3 SURMOUNT-MAINTENANCE study, which is testing tirzepatide maintenance at varying doses after weight loss. Results are expected in late 2026.
What clinicians who prescribe microdoses tend to say, off the record, is that most patients can hold their weight loss on roughly half the maintenance dose, and a meaningful subset can hold on a quarter. This matches the broader pharmacology: GLP-1 receptor activation is not strictly linear with dose, especially for appetite suppression.
Microdosing semaglutide vs tirzepatide
The two drugs behave a little differently when you reduce the dose:
| Question | Semaglutide (Wegovy / compounded) | Tirzepatide (Zepbound / compounded) |
|---|---|---|
| Typical microdose range | 0.25mg to 1.2mg weekly | 2.5mg to 7.5mg weekly |
| Half-life | About 7 days, steady-state at 4-5 weeks | About 5 days, steady-state at 4 weeks |
| Side effect reduction at low dose | Substantial. Nausea drops sharply below 1.0mg | More modest. GI side effects do not fully resolve until below 5.0mg |
| Appetite suppression at low dose | Surprisingly preserved. Many patients still feel "the food noise quieting" at 0.5mg | Preserved, but cravings creep back faster than with semaglutide |
| Compounded availability | Wide. Compounded semaglutide remains accessible through licensed providers | Restricted. Compounded tirzepatide came off the FDA shortage list in February 2026; new prescriptions are limited to specific medical exceptions |
That last row is the legal change that has reshaped the microdosing conversation in 2026. If you are considering tirzepatide microdosing specifically, read the full status update in our compounded-vs-branded tirzepatide guide before you do anything else.
How to do it without making it worse
If you are considering microdosing, the bar is "do it with a prescriber" rather than "calculate it yourself with a calibrated syringe and a Reddit thread." A few practical points:
- Bring it up explicitly. Most providers will not volunteer the conversation. Tell them what you want to try, why, and ask whether their clinic has experience with sub-label dosing.
- Do not switch products mid-microdose. If you are on branded Wegovy, do not quietly start splitting it across multiple injections. The prefilled pens deliver fixed doses and re-using them adds infection risk. Compounded vials are dose-flexible by design and are the right format if you need flexibility.
- Track for at least 4 weeks before adjusting. GLP-1 effects do not move on a dose change for several weeks. Patients who lower the dose and panic three days later usually have not given the new level time to settle.
- Watch the rebound markers. If your hunger returns to pre-medication levels and the scale starts climbing, the dose was too low. That is the most informative signal.
- Do not stop labs. Most clinicians ask for liver and lipid panels every six months on GLP-1s. That does not change at lower doses.
Where to find a clinician who will actually consider it
Most large general telehealth GLP-1 services operate on standardized protocols and will not entertain off-label dose conversations. The clinicians who consider microdosing are usually in three groups:
- Obesity medicine specialists in private practice. Look for the ABOM (American Board of Obesity Medicine) credential.
- Smaller telehealth services with named clinicians, especially the ones that publish their dosing philosophy on their site.
- Concierge or direct-care primary care clinicians who already have a relationship with you and are not running on 12-minute visits.
Take our provider-matching quiz if you want to filter the directory by clinics that explicitly offer dose flexibility, or browse GLP-1 clinics in your state and check which list maintenance-dose programs in their service descriptions.